Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer

Phase 2

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-08-24

Last Posted Date: 2023-08-24

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 20

Registration Number: NCT06009848

Locations: 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cadonilimab
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2023-08-21

Last Posted Date: 2023-08-21

Lead Sponsor: Qian Chu

Target Recruit Count: 49

Registration Number: NCT06001151

Locations: 🇨🇳
Qian Chu, Wuhan, Hubei, China

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3

Not yet recruiting

Conditions: Locally Advanced or Metastatic NSCLC

Interventions: Drug: AK104
Drug: Tislelizumab
Drug: carboplatin
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Akeso

Target Recruit Count: 642

Registration Number: NCT05990127

Locations: 🇨🇳
The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳
Cancer hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, Beijing, China

and more 59 locations

Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: AK104
Drug: Capecitabine
Radiation: Neoadjuvant Radiotherapy

First Posted Date: 2023-08-08

Last Posted Date: 2024-02-07

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 33

Registration Number: NCT05980689

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Phase 2

Recruiting

Conditions: Cholangiocarcinoma Non-resectable

Interventions: Drug: Candonilimab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2023-08-07

Last Posted Date: 2023-08-07

Lead Sponsor: West China Hospital

Target Recruit Count: 65

Registration Number: NCT05978609

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Locally Advanced Unresectable Gastric Adenocarcinoma

Interventions: Drug: Oxaliplatin
Drug: Capecitabine
Drug: Cadonilimab

First Posted Date: 2023-08-03

Last Posted Date: 2023-08-03

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT05974059

Locations: 🇨🇳
Xuewei Ding, Tianjin, Tianjin, China

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2

Recruiting

Conditions: Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: AK117
Drug: Oxaliplatin
Drug: Docetaxel
Drug: Tegafur-gimeracil-oteracil potassium
Drug: 5-Fluorouracil

First Posted Date: 2023-07-27

Last Posted Date: 2023-11-18

Lead Sponsor: Akeso

Target Recruit Count: 90

Registration Number: NCT05960955

Locations: 🇨🇳
Tianjin Provincial Tumor Hospital, Tianjin, China

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SPH4336
Drug: Cadonilimab

First Posted Date: 2023-07-13

Last Posted Date: 2024-11-28

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 63

Registration Number: NCT05944224

Locations: 🇨🇳
The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

and more 13 locations

A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer

Phase 2

Not yet recruiting

Conditions: Vulvar Cancer

Interventions: Drug: AK104

First Posted Date: 2023-07-06

Last Posted Date: 2023-07-06

Lead Sponsor: Akeso

Target Recruit Count: 20

Registration Number: NCT05932212

Locations: 🇨🇳
Sun Yant-Sen Memorial Hospital, Guangzhou, Guangdong, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiangzhuang, Hebei, China

and more 3 locations

Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Candonilimab

First Posted Date: 2023-07-03

Last Posted Date: 2024-04-17

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 27

Registration Number: NCT05926700

Locations: 🇨🇳
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy